Last reviewed · How we verify
Mirasol-treated Fresh Whole Blood
Mirasol-treated Fresh Whole Blood is a Pathogen reduction technology / Blood product Biologic drug developed by Johns Hopkins University. It is currently in Phase 3 development for Fresh whole blood for transfusion with reduced risk of pathogen transmission and TRALI.
Mirasol treatment uses riboflavin and ultraviolet light to inactivate pathogens and reduce white blood cells in fresh whole blood for transfusion.
Mirasol treatment uses riboflavin and ultraviolet light to inactivate pathogens and reduce white blood cells in fresh whole blood for transfusion. Used for Fresh whole blood for transfusion with reduced risk of pathogen transmission and TRALI.
At a glance
| Generic name | Mirasol-treated Fresh Whole Blood |
|---|---|
| Sponsor | Johns Hopkins University |
| Drug class | Pathogen reduction technology / Blood product |
| Modality | Biologic |
| Therapeutic area | Hematology / Transfusion Medicine |
| Phase | Phase 3 |
Mechanism of action
The Mirasol pathogen reduction technology involves treating blood with riboflavin (vitamin B2) and ultraviolet A light, which generates reactive oxygen species that damage nucleic acids in pathogens and leukocytes. This process reduces the risk of transfusion-transmitted infections and transfusion-related acute lung injury (TRALI) while maintaining the hemostatic function of the blood product.
Approved indications
- Fresh whole blood for transfusion with reduced risk of pathogen transmission and TRALI
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reactions
- Hemolytic transfusion reactions
Key clinical trials
- Mirasol Evaluation of Reduction in Infections Trial (PHASE3)
- Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood (NA)
- Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirasol-treated Fresh Whole Blood CI brief — competitive landscape report
- Mirasol-treated Fresh Whole Blood updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI
Frequently asked questions about Mirasol-treated Fresh Whole Blood
What is Mirasol-treated Fresh Whole Blood?
How does Mirasol-treated Fresh Whole Blood work?
What is Mirasol-treated Fresh Whole Blood used for?
Who makes Mirasol-treated Fresh Whole Blood?
What drug class is Mirasol-treated Fresh Whole Blood in?
What development phase is Mirasol-treated Fresh Whole Blood in?
What are the side effects of Mirasol-treated Fresh Whole Blood?
Related
- Drug class: All Pathogen reduction technology / Blood product drugs
- Manufacturer: Johns Hopkins University — full pipeline
- Therapeutic area: All drugs in Hematology / Transfusion Medicine
- Indication: Drugs for Fresh whole blood for transfusion with reduced risk of pathogen transmission and TRALI
- Compare: Mirasol-treated Fresh Whole Blood vs similar drugs
- Pricing: Mirasol-treated Fresh Whole Blood cost, discount & access